Gene
SH2B3
SH2B3 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (2), Actionable biomarkers (6), Trial mentions (9), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention SH2B3. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
SH2B3 has 9 trial mentions across 6 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 2 of 8,875 | 0.02% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 5 of 11,460 | 0.04% |
| 2022 | 2 of 8,285 | 0.02% | 8 of 13,598 | 0.06% |
| 2021 | 0 of 8,692 | 0.00% | 10 of 15,045 | 0.07% |
| 2020 | 0 of 7,640 | 0.00% | 3 of 14,459 | 0.02% |
| 2019 | 1 of 7,300 | 0.01% | 3 of 12,159 | 0.02% |
| 2018 | 0 of 6,927 | 0.00% | 10 of 11,854 | 0.08% |
| 2017 | 0 of 6,558 | 0.00% | 3 of 11,595 | 0.03% |
Showing 10 of 37 years.
Assay-provider ledger (2)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| AmpliSeq | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | September 01, 2016 |
| Ion Torrent Personal Genome Machine | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | September 01, 2016 |
Actionable biomarkers (6)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| SH2B3 deletion | Jak Inhibitors | response-associated | Myelodysplastic/Myeloproliferative Neoplasm | Cancer Genome Interpreter |
| SH2B3 oncogenic mutation | Jak Inhibitors | response-associated | Myelodysplastic/Myeloproliferative Neoplasm | Cancer Genome Interpreter |
| IL7R (S185C) + SH2B3 deletion | Ruxolitinib | response-associated | acute lymphoblastic leukemia | Cancer Genome Interpreter |
| IL7R inframe insertion (237-255),inframe deletion (237-255) + SH2B3 deletion | Ruxolitinib | response-associated | acute lymphoblastic leukemia | Cancer Genome Interpreter |
| IL7R (S185C) + SH2B3 deletion | Mtor Inhibitors | response-associated | acute lymphoblastic leukemia | Cancer Genome Interpreter |
Showing 5 of 6 actionable-biomarker assertions.
Trial mentions (9)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT02823210 | Trial biospecimen (AACT) |
| NCT02723994 | Trial eligibility (AACT) |
| NCT06905106 | Trial eligibility (AACT) |
| NCT01164163 | Trial eligibility (AACT) |
| NCT03571321 | Trial eligibility (AACT) |
Showing 5 of 9 trial mentions.
Target-disease associations (1,013)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2) measurement | measurement | GWAS credible sets |
| ACPA-positive rheumatoid arthritis | immune system disease | GWAS credible sets |
| Abnormal thrombosis | phenotype | GWAS credible sets |
| Abnormality of metabolism/homeostasis | phenotype | GWAS credible sets |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
Showing 5 of 1,013 associations.
Vendor sourcing (51)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The SH2B3 c.1198G>A; p.Glu400Lys variant (rs72650673, ClinVar variation ID 501686) is reported in the literature in individuals with idiopathic erythrocytosi... | View ClinVar record SCV007331346.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The p.L501F variant (also known as c.1501C>T), located in coding exon 7 of the SH2B3 gene, results from a C to T substitution at nucleotide position 1501. Th... | View ClinVar record SCV003557866.3 |
| Assistance Publique – Hôpitaux de Paris | Trial sponsor | Biospecimen collected in a trialTrial biospecimen collection | No supporting text recorded; see the citation. | View trial NCT02823210 |
| Assistance Publique – Hôpitaux de Paris | Trial sponsor | Mentioned in trial textTrial free-text mention | LNK | View trial NCT02823210 |
| Centre Hospitalier Universitaire Dijon | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : \- Persons who have given their non-opposition Patients with polycythemia: * haemoglobin value \> 16 g/dl female or \> 16.5 g/dl male * with a well-iden... | View trial NCT06905106 |
Showing 5 of 51 sourcing records.
Trial-cited literature (75)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Pathogenesis of allergic diseases and implications for therapeutic interventions. | Signal transduction and targeted therapy | 2023 | 286 |
| Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events. | Cancers | 2023 | 82 |
| An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial. | Frontiers in immunology | 2023 | 14 |
| Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. | Cell reports. Medicine | 2023 | 8 |
| Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay. | JCO precision oncology | 2023 | 2 |
Showing 5 of 75 papers.
Protein variant mentions (9)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.E395K | 1 | 2015 | PMID 25741868 |
| p.E400K | 1 | 2015 | PMID 25741868 |
| p.E78K | 1 | 2020 | PMID 32629392 |
| p.L142F | 1 | 2015 | PMID 25741868 |
| p.P344L | 1 | 2015 | PMID 25741868 |
Showing 5 of 9 variants.
Literature-extracted relations (8)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Diabetes Mellitus | Disease | associate |
Predictors of the Initiation of Islet Autoimmunity and Progression to Multiple Autoantibodies and Clinical Diabetes: The TEDDY Study. | 2022 |
| Diabetes Mellitus, Type 1 | Disease | associate |
Predictors of the Initiation of Islet Autoimmunity and Progression to Multiple Autoantibodies and Clinical Diabetes: The TEDDY Study. | 2022 |
| Hypertension | Disease | associate |
Effects of established blood pressure loci on blood pressure values and hypertension risk in an Algerian population sample. | 2015 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | Disease | associate |
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. | 2014 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | Disease | associate |
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. | 2012 |
Showing 5 of 8 relation assertions.
Organizations publishing (177)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Novant Health | Hospital | 7 | 2012 to 2021 |
| State University System of Florida | Academic | 7 | 2012 to 2022 |
| Mayo Clinic | Hospital | 6 | 2010 to 2018 |
| Government of the United States of America | Government | 5 | 2015 to 2022 |
| University of London | Academic | 5 | 2009 to 2021 |
Showing 5 of 177 organizations.
Where SH2B3 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- psychiatric disorder
- respiratory or thoracic disease
- urinary system disease
938 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.